Summary -

Key Takeaways Explained for a Non-Medical Audience

– Epidemiological studies show an increased cancer risk in individuals with type 2 diabetes and obesity, partly due to hyperinsulinemia from insulin resistance.

– Hyperinsulinemia elevates IGF-I expression, which, along with IGF-II, is associated with tumor growth in vitro, animal models, and human studies.

– Insulin binds primarily to insulin receptors (IR-A and IR-B), while IGF-I and IGF-II interact with IGF-I receptors (IGF-IR) and hybrid receptors, influencing tumor development.

– IR-A, more mitogenic than IR-B, is overexpressed in many cancer cells, enhancing insulin’s role in promoting cell proliferation.

– The PI3K/Akt/mTOR pathway, activated by insulin and IGFs, drives protein synthesis and cell growth, contributing to tumorigenesis.

– The Ras/MAPK/ERK pathway, also activated by insulin and IGFs, promotes cell proliferation and survival, further linking these hormones to cancer.

– Loss of tumor suppressor PTEN leads to constitutively active mTOR, enhancing cancer cell resistance to treatments like trastuzumab and tamoxifen.

– Metformin reduces circulating insulin levels by decreasing hepatic gluconeogenesis and activates AMPK, inhibiting mTOR and potentially reducing tumor growth.

– Thiazolidinediones (TZDs) improve insulin sensitivity but show inconsistent anti-neoplastic effects in clinical studies.

– Monoclonal antibodies targeting IGF-I and IGF-II prevent mitogenic signaling through IGF-IR and hybrid receptors, offering potential cancer therapies.

– Tyrosine kinase inhibitors targeting IGF-IR may also affect IR, impacting both mitogenic and metabolic signaling pathways.

– Overexpression of IGF-II due to loss of imprinting is linked to increased tumor development in colon cancer models.

– Animal studies demonstrate that hyperinsulinemia promotes mammary tumor growth, which can be reduced by lowering insulin levels.

– High IGF-IR expression in tumors is associated with resistance to radiotherapy and lower patient survival.

– Insulin and IGFs inhibit hepatic synthesis of sex hormone-binding globulin, increasing sex steroid bioavailability, which may promote breast and endometrial cancer.